BioStock: New promising data from Scandion Oncology’s cancer study
At the end of last week, Scandion Oncology reported phase II data from the first cohort of chemotherapy-resistant colorectal cancer patients treated with the company’s drug candidate SCO-101 in combination with the standard chemotherapy FOLFIRI. The results are encouraging for the further development of the candidate.
Read the full article about Scandion Oncology at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/